{"id":327926,"date":"2025-08-01T06:05:00","date_gmt":"2025-08-01T06:05:00","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/will-pfizer-stock-go-up-2\/"},"modified":"2025-08-01T06:05:00","modified_gmt":"2025-08-01T06:05:00","slug":"will-pfizer-stock-go-up","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","title":{"rendered":"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":251337,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[20],"tags":[28,45,44],"class_list":["post-327926","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-trading","tag-investment","tag-stock","tag-strategy"],"acf":{"h1":"Pocket Option'un Kesin Analizi: Pfizer Hissesi Y\u00fckselecek mi?","h1_source":{"label":"H1","type":"text","formatted_value":"Pocket Option'un Kesin Analizi: Pfizer Hissesi Y\u00fckselecek mi?"},"description":"Pfizer hisselerinin y\u00fckselip y\u00fckselmeyece\u011fine dair kapsaml\u0131 analizi, \u00f6zel de\u011ferleme y\u00f6ntemleri, finansal metrikler ve sekt\u00f6r korelasyonlar\u0131 ile ke\u015ffedin. Pocket Option'\u0131n faydal\u0131, benzersiz, somut ve acil yat\u0131r\u0131mc\u0131 \u00d6\u011frenimi.","description_source":{"label":"Description","type":"textarea","formatted_value":"Pfizer hisselerinin y\u00fckselip y\u00fckselmeyece\u011fine dair kapsaml\u0131 analizi, \u00f6zel de\u011ferleme y\u00f6ntemleri, finansal metrikler ve sekt\u00f6r korelasyonlar\u0131 ile ke\u015ffedin. Pocket Option'\u0131n faydal\u0131, benzersiz, somut ve acil yat\u0131r\u0131mc\u0131 \u00d6\u011frenimi."},"intro":"Pfizer hisselerinin y\u00fckselip y\u00fckselmeyece\u011fini tahmin etmek, y\u00fczeysel analizden daha fazlas\u0131n\u0131 gerektirir. Bu derinlemesine inceleme, bir\u00e7ok yat\u0131r\u0131mc\u0131n\u0131n akl\u0131ndaki soruya cevap vermek i\u00e7in nicel modelleme, sekt\u00f6re \u00f6zg\u00fc de\u011ferlemeler ve \u00f6zel tahmin metodolojilerini birle\u015ftirir: Pfizer hisseleri y\u00fckselecek mi? Tipik piyasa yorumlar\u0131n\u0131n aksine, veri odakl\u0131 kararlar almak i\u00e7in sofistike yat\u0131r\u0131mc\u0131lar\u0131n kulland\u0131\u011f\u0131 matematiksel korelasyonlar, istatistiksel g\u00f6stergeler ve \u00e7ok fakt\u00f6rl\u00fc analiz modellerini inceleyece\u011fiz.","intro_source":{"label":"Intro","type":"text","formatted_value":"Pfizer hisselerinin y\u00fckselip y\u00fckselmeyece\u011fini tahmin etmek, y\u00fczeysel analizden daha fazlas\u0131n\u0131 gerektirir. Bu derinlemesine inceleme, bir\u00e7ok yat\u0131r\u0131mc\u0131n\u0131n akl\u0131ndaki soruya cevap vermek i\u00e7in nicel modelleme, sekt\u00f6re \u00f6zg\u00fc de\u011ferlemeler ve \u00f6zel tahmin metodolojilerini birle\u015ftirir: Pfizer hisseleri y\u00fckselecek mi? Tipik piyasa yorumlar\u0131n\u0131n aksine, veri odakl\u0131 kararlar almak i\u00e7in sofistike yat\u0131r\u0131mc\u0131lar\u0131n kulland\u0131\u011f\u0131 matematiksel korelasyonlar, istatistiksel g\u00f6stergeler ve \u00e7ok fakt\u00f6rl\u00fc analiz modellerini inceleyece\u011fiz."},"body_html":"<h2>Pfizer Hisse Senedi Y\u00f6n\u00fcn\u00fc Tahmin Etmek \u0130\u00e7in \u00c7ok Fakt\u00f6rl\u00fc Yakla\u015f\u0131m<\/h2>\nYat\u0131r\u0131mc\u0131lar \"Pfizer hisse senedi y\u00fckselecek mi\" diye sorduklar\u0131nda, genellikle basit evet\/hay\u0131r cevaplar\u0131 ararlar. Ancak, Pocket Option gibi kurumlarda profesyonel yat\u0131r\u0131mc\u0131lar, ila\u00e7 hisse senedi tahmininin \u00e7ok y\u00f6nl\u00fc bir yakla\u015f\u0131m gerektirdi\u011fini anlarlar. \u0130la\u00e7 end\u00fcstrisinin k\u00f6\u015fe ta\u015flar\u0131ndan biri olan Pfizer (NYSE: PFE), ayn\u0131 anda birka\u00e7 boyutta analiz gerektirir.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Analiz Boyutu<\/th>\n<th>Anahtar Metrikler<\/th>\n<th>Tahmin Modelindeki A\u011f\u0131rl\u0131k<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Finansal Sa\u011fl\u0131k<\/td>\n<td>FCF Getirisi, Bor\u00e7\/EBITDA, Faiz Kar\u015f\u0131lama<\/td>\n<td>%25<\/td>\n<\/tr>\n<tr>\n<td>\u00dcr\u00fcn Hatt\u0131<\/td>\n<td>Faz Ge\u00e7i\u015f Olas\u0131l\u0131klar\u0131, Gelir Potansiyeli<\/td>\n<td>%30<\/td>\n<\/tr>\n<tr>\n<td>Rekabet\u00e7i Konum<\/td>\n<td>Pazar Pay\u0131, Patent U\u00e7urumu Maruziyeti<\/td>\n<td>%20<\/td>\n<\/tr>\n<tr>\n<td>Makro \u00c7evre<\/td>\n<td>Sa\u011fl\u0131k Politikas\u0131, Faiz Oranlar\u0131, Sekt\u00f6r Rotasyonu<\/td>\n<td>%15<\/td>\n<\/tr>\n<tr>\n<td>De\u011ferleme Metrikleri<\/td>\n<td>P\/E, EV\/EBITDA, PEG Oran\u0131<\/td>\n<td>%10<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBu a\u011f\u0131rl\u0131kl\u0131 yakla\u015f\u0131m, ila\u00e7 hisse senedi hareketlerini tahmin etmenin arkas\u0131ndaki karma\u015f\u0131kl\u0131\u011f\u0131 kabul eden kapsaml\u0131 bir analiz \u00e7er\u00e7evesi olu\u015fturur. Pocket Option'daki deneyimli analistler, bu boyutlar\u0131 kendi \u00f6zel hisse senedi de\u011ferlendirme modellerinde kullan\u0131rlar.\n<h2>Kantitatif Analiz: Pfizer'in Potansiyel De\u011fer Art\u0131\u015f\u0131n\u0131n Arkas\u0131ndaki Say\u0131lar<\/h2>\n\"Pfizer hisse senedi y\u00fckselecek mi\" sorusu, tarihsel kal\u0131plar\u0131n ve korelasyonlar\u0131n titiz matematiksel analizi ile k\u0131smen yan\u0131tlanabilir. \u0130leri d\u00fczey yat\u0131r\u0131mc\u0131lar, \u00f6l\u00e7\u00fclebilir metriklere dayal\u0131 olas\u0131 fiyat hareketlerini belirlemek i\u00e7in istatistiksel ara\u00e7lar kullan\u0131r.\n<h3>Pfizer'in Tarihsel Performans Fakt\u00f6rlerinin Regresyon Analizi<\/h3>\n\u00c7oklu regresyon modelleri, Pfizer'in hisse senedi fiyat hareketlerini tarihsel olarak hangi fakt\u00f6rlerin etkiledi\u011fini ortaya koyar. Analizimiz, en istatistiksel olarak anlaml\u0131 de\u011fi\u015fkenleri belirlemek i\u00e7in 14 y\u0131ll\u0131k \u00fc\u00e7 ayl\u0131k verileri inceledi.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>De\u011fi\u015fken<\/th>\n<th>Katsay\u0131<\/th>\n<th>p-de\u011feri<\/th>\n<th>\u00d6nem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gelir B\u00fcy\u00fcmesi (YoY)<\/td>\n<td>0.72<\/td>\n<td>0.003<\/td>\n<td>Y\u00fcksek<\/td>\n<\/tr>\n<tr>\n<td>Ar-Ge Harcamas\u0131\/Gelir<\/td>\n<td>0.58<\/td>\n<td>0.008<\/td>\n<td>Y\u00fcksek<\/td>\n<\/tr>\n<tr>\n<td>Br\u00fct Kar Marj\u0131<\/td>\n<td>0.41<\/td>\n<td>0.022<\/td>\n<td>Orta<\/td>\n<\/tr>\n<tr>\n<td>FDA Onaylar\u0131 (son 12 ay)<\/td>\n<td>0.39<\/td>\n<td>0.031<\/td>\n<td>Orta<\/td>\n<\/tr>\n<tr>\n<td>Patent S\u00fcrelerinin Dolmas\u0131 (\u00f6n\u00fcm\u00fczdeki 24 ay)<\/td>\n<td>-0.64<\/td>\n<td>0.005<\/td>\n<td>Y\u00fcksek (negatif)<\/td>\n<\/tr>\n<tr>\n<td>Sa\u011fl\u0131k Sekt\u00f6r\u00fc Performans\u0131<\/td>\n<td>0.37<\/td>\n<td>0.042<\/td>\n<td>Orta<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBu regresyon analizi, gelir b\u00fcy\u00fcmesi ve Ar-Ge yat\u0131r\u0131m verimlili\u011finin tarihsel olarak Pfizer'in hisse senedi performans\u0131 i\u00e7in en g\u00fc\u00e7l\u00fc pozitif g\u00f6stergeler oldu\u011funu, yakla\u015fan patent s\u00fcrelerinin dolmas\u0131n\u0131n ise en \u00f6nemli negatif fakt\u00f6r oldu\u011funu g\u00f6stermektedir. Model, yakla\u015f\u0131k %73'l\u00fck bir R-kare de\u011feri elde etti ve bu, tarihsel fiyat hareketlerinin yakla\u015f\u0131k %73'\u00fcn\u00fc a\u00e7\u0131klad\u0131\u011f\u0131n\u0131 \u00f6ne s\u00fcrmektedir.\n\nPocket Option'daki sofistike yat\u0131r\u0131mc\u0131lar, Pfizer hisse senedinin de\u011fer kazan\u0131p kazanmayaca\u011f\u0131n\u0131 de\u011ferlendirirken bu istatistiksel ili\u015fkileri tahmin modellerine dahil ederler.\n<h2>Boru Hatt\u0131 De\u011fer Hesaplamas\u0131: Gelecek B\u00fcy\u00fcmenin Matematiksel Temeli<\/h2>\nPfizer gibi ila\u00e7 \u015firketleri i\u00e7in gelecekteki hisse de\u011fer art\u0131\u015f\u0131, b\u00fcy\u00fck \u00f6l\u00e7\u00fcde ila\u00e7 geli\u015ftirme boru hatlar\u0131na ba\u011fl\u0131d\u0131r. Profesyonel analistler, her boru hatt\u0131 aday\u0131n\u0131n Net Bug\u00fcnk\u00fc De\u011ferini (NPV), olas\u0131l\u0131kla ayarlanm\u0131\u015f nakit ak\u0131\u015f\u0131 projeksiyonlar\u0131 kullanarak hesaplarlar.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Geli\u015ftirme A\u015famas\u0131<\/th>\n<th>Tipik Ba\u015far\u0131 Olas\u0131l\u0131\u011f\u0131<\/th>\n<th>Pfizer'in Tarihsel Ba\u015far\u0131 Oran\u0131<\/th>\n<th>Sekt\u00f6r K\u0131yaslamas\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Preklinikten Faz 1'e<\/td>\n<td>%35<\/td>\n<td>%38.2<\/td>\n<td>%33.6<\/td>\n<\/tr>\n<tr>\n<td>Faz 1'den Faz 2'ye<\/td>\n<td>%63<\/td>\n<td>%66.7<\/td>\n<td>%61.5<\/td>\n<\/tr>\n<tr>\n<td>Faz 2'den Faz 3'e<\/td>\n<td>%31<\/td>\n<td>%37.4<\/td>\n<td>%30.7<\/td>\n<\/tr>\n<tr>\n<td>Faz 3'ten Onaya<\/td>\n<td>%58<\/td>\n<td>%62.3<\/td>\n<td>%58.1<\/td>\n<\/tr>\n<tr>\n<td>Genel (Preklinikten Pazara)<\/td>\n<td>%4<\/td>\n<td>%5.9<\/td>\n<td>%3.8<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nPfizer hisse senedi y\u00fckselecek mi de\u011ferlendirmesi yaparken, her boru hatt\u0131 aday\u0131n\u0131n risk ayarl\u0131 Net Bug\u00fcnk\u00fc De\u011ferini (rNPV) hesaplamak i\u00e7in a\u015fa\u011f\u0131daki form\u00fcl\u00fc uygulayabiliriz:\n\nrNPV = \u03a3 [(Gelir<sub>t<\/sub> \u00d7 Marj - Maliyetler<sub>t<\/sub>) \u00d7 Ba\u015far\u0131 Olas\u0131l\u0131\u011f\u0131] \/ (1 + r)<sup>t<\/sup>\n\nBurada:\n<ul>\n \t<li>Gelir<sub>t<\/sub> = Y\u0131l t'deki tahmini gelir<\/li>\n \t<li>Marj = Beklenen kar marj\u0131<\/li>\n \t<li>Maliyetler<sub>t<\/sub> = Y\u0131l t'deki geli\u015ftirme ve pazarlama maliyetleri<\/li>\n \t<li>r = \u0130skonto oran\u0131 (genellikle ila\u00e7 projeleri i\u00e7in %10-12)<\/li>\n \t<li>t = Y\u0131l (pazara \u00e7\u0131k\u0131\u015ftan patent s\u00fcresinin dolmas\u0131na kadar)<\/li>\n<\/ul>\n<h3>Pfizer'in Boru Hatt\u0131n\u0131 Sekt\u00f6r Standartlar\u0131yla K\u0131yaslama<\/h3>\nPfizer'in boru hatt\u0131 de\u011feri, Pocket Option analistleri taraf\u0131ndan hesaplanan birka\u00e7 anahtar metrik kullan\u0131larak sekt\u00f6rdeki akranlar\u0131yla nicel olarak kar\u015f\u0131la\u015ft\u0131r\u0131labilir:\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Metrik<\/th>\n<th>Pfizer<\/th>\n<th>Sekt\u00f6r Ortalamas\u0131<\/th>\n<th>G\u00f6receli Konum<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Boru Hatt\u0131 NPV\/Piyasa De\u011feri<\/td>\n<td>0.31<\/td>\n<td>0.26<\/td>\n<td>%19.2+<\/td>\n<\/tr>\n<tr>\n<td>Ar-Ge Verimlili\u011fi (NPV\/Ar-Ge $)<\/td>\n<td>2.7<\/td>\n<td>2.4<\/td>\n<td>%12.5+<\/td>\n<\/tr>\n<tr>\n<td>Ge\u00e7 A\u015fama Varl\u0131klar (boru hatt\u0131 de\u011ferinin %'si)<\/td>\n<td>%62<\/td>\n<td>%58<\/td>\n<td>%6.9+<\/td>\n<\/tr>\n<tr>\n<td>Teknik Ba\u015far\u0131 Olas\u0131l\u0131\u011f\u0131 Ortalamas\u0131<\/td>\n<td>%23.8<\/td>\n<td>%21.3<\/td>\n<td>%11.7+<\/td>\n<\/tr>\n<tr>\n<td>Boru Hatt\u0131 \u00c7e\u015fitlendirme Endeksi<\/td>\n<td>0.72<\/td>\n<td>0.68<\/td>\n<td>%5.9+<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBu hesaplamalar, Pfizer'in boru hatt\u0131n\u0131n \u015fu anda piyasa de\u011ferine g\u00f6re ortalaman\u0131n \u00fczerinde bir de\u011fere sahip oldu\u011funu ve geleneksel metriklerle d\u00fc\u015f\u00fck de\u011ferlenmi\u015f olabilece\u011fini g\u00f6stermektedir. Bu nicel yakla\u015f\u0131m, Pocket Option gibi platformlardaki yat\u0131r\u0131mc\u0131lara, Pfizer hisse senedinin geli\u015fimsel varl\u0131klar\u0131na dayal\u0131 olarak de\u011fer kazanma potansiyeline sahip olup olmad\u0131\u011f\u0131n\u0131 belirlemelerine yard\u0131mc\u0131 olur.\n<h2>Finansal Oran Analizi: Geleneksel Metriklerin \u00d6tesinde<\/h2>\nPfizer hisse senedinin de\u011fer kazan\u0131p kazanmayaca\u011f\u0131n\u0131 do\u011fru bir \u015fekilde tahmin etmek i\u00e7in sofistike yat\u0131r\u0131mc\u0131lar, temel P\/E kar\u015f\u0131la\u015ft\u0131rmalar\u0131n\u0131n \u00f6tesine ge\u00e7en geli\u015fmi\u015f finansal oranlar\u0131 analiz ederler. Bu metrikler, de\u011fer yaratma potansiyeline dair matematiksel i\u00e7g\u00f6r\u00fcler sa\u011flar.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Geli\u015fmi\u015f Oran<\/th>\n<th>Form\u00fcl<\/th>\n<th>Pfizer Mevcut<\/th>\n<th>Pfizer 5 Y\u0131ll\u0131k Ort.<\/th>\n<th>Sekt\u00f6r Ortancas\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ekonomik Katma De\u011fer (EVA)<\/td>\n<td>NOPAT - (WACC \u00d7 Yat\u0131r\u0131lan Sermaye)<\/td>\n<td>$6.82B<\/td>\n<td>$5.43B<\/td>\n<td>$3.21B<\/td>\n<\/tr>\n<tr>\n<td>Nakit Getirisi\/Yat\u0131r\u0131lan Sermaye<\/td>\n<td>FCF\/Yat\u0131r\u0131lan Sermaye<\/td>\n<td>%11.7<\/td>\n<td>%10.3<\/td>\n<td>%9.8<\/td>\n<\/tr>\n<tr>\n<td>EBITDA\/\u0130\u015fletme De\u011feri<\/td>\n<td>EBITDA\/EV<\/td>\n<td>%9.2<\/td>\n<td>%8.6<\/td>\n<td>%7.9<\/td>\n<\/tr>\n<tr>\n<td>Ar-Ge Etkinlik Oran\u0131<\/td>\n<td>Yeni \u00dcr\u00fcn Geliri\/Ar-Ge Gideri (t-3)<\/td>\n<td>2.83<\/td>\n<td>2.67<\/td>\n<td>2.41<\/td>\n<\/tr>\n<tr>\n<td>Patent Ayarl\u0131 P\/E<\/td>\n<td>P\/E \u00d7 (1 + Patent S\u00fcresi Fakt\u00f6r\u00fc)<\/td>\n<td>12.8<\/td>\n<td>14.1<\/td>\n<td>15.7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBu geli\u015fmi\u015f finansal metrikler, Pfizer'in sermaye maliyetinin \u00fczerinde getiri sa\u011flama yetene\u011fini (EVA) ve Ar-Ge yat\u0131r\u0131mlar\u0131n\u0131 karl\u0131 \u00fcr\u00fcnlere d\u00f6n\u00fc\u015ft\u00fcrme verimlili\u011fini ortaya koyar. CROCI ve Ar-Ge Etkinli\u011fi'ndeki olumlu e\u011filimler, operasyonel verimlili\u011fin artt\u0131\u011f\u0131n\u0131 g\u00f6sterirken, patent ayarl\u0131 P\/E, fikri m\u00fclkiyet varl\u0131klar\u0131 dikkate al\u0131nd\u0131\u011f\u0131nda potansiyel d\u00fc\u015f\u00fck de\u011ferlemeyi i\u015faret eder.\n\nPocket Option'\u0131n analitik ekibi, \"PFE hisse senedi y\u00fckselecek mi?\" sorusunu yan\u0131tlarken bu n\u00fcansl\u0131 finansal metriklere vurgu yapar. Ba\u015fl\u0131k rakamlar\u0131na g\u00fcvenmek yerine, bu matematiksel olarak titiz yakla\u015f\u0131m, de\u011fer yaratma potansiyeline dair daha derin i\u00e7g\u00f6r\u00fcler sa\u011flar.\n<h2>Pfizer'in Gelir \u00c7e\u015fitlendirmesinin Hisse \u0130stikrar\u0131na Etkisini Modelleme<\/h2>\nGelir yo\u011funla\u015fma riski, ila\u00e7 hisse senedi oynakl\u0131\u011f\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkiler. \u00dcr\u00fcn segmentleri aras\u0131ndaki \u00e7e\u015fitlendirme endekslerini ve korelasyon katsay\u0131lar\u0131n\u0131 hesaplayarak, Pfizer'in gelir yap\u0131s\u0131n\u0131n hisse istikrar\u0131n\u0131 nas\u0131l etkiledi\u011fini nicel olarak de\u011ferlendirebiliriz.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Segment<\/th>\n<th>Gelir Katk\u0131s\u0131<\/th>\n<th>B\u00fcy\u00fcme Oran\u0131 (CAGR)<\/th>\n<th>Patent Korumas\u0131 (A\u011f\u0131rl\u0131kl\u0131 Ort.)<\/th>\n<th>Genel Hisse Performans\u0131na Korelasyon<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>A\u015f\u0131lar<\/td>\n<td>%21.7<\/td>\n<td>%7.3<\/td>\n<td>6.8 y\u0131l<\/td>\n<td>0.67<\/td>\n<\/tr>\n<tr>\n<td>Onkoloji<\/td>\n<td>%18.5<\/td>\n<td>%12.4<\/td>\n<td>8.2 y\u0131l<\/td>\n<td>0.78<\/td>\n<\/tr>\n<tr>\n<td>\u0130nflamasyon &amp; \u0130mm\u00fcnoloji<\/td>\n<td>%16.2<\/td>\n<td>%8.9<\/td>\n<td>7.5 y\u0131l<\/td>\n<td>0.59<\/td>\n<\/tr>\n<tr>\n<td>\u0130\u00e7 Hastal\u0131klar\u0131<\/td>\n<td>%15.7<\/td>\n<td>%3.7<\/td>\n<td>4.3 y\u0131l<\/td>\n<td>0.42<\/td>\n<\/tr>\n<tr>\n<td>Nadir Hastal\u0131k<\/td>\n<td>%11.4<\/td>\n<td>%15.8<\/td>\n<td>9.6 y\u0131l<\/td>\n<td>0.71<\/td>\n<\/tr>\n<tr>\n<td>Hastane<\/td>\n<td>%9.8<\/td>\n<td>%5.1<\/td>\n<td>5.7 y\u0131l<\/td>\n<td>0.38<\/td>\n<\/tr>\n<tr>\n<td>Di\u011ferleri<\/td>\n<td>%6.7<\/td>\n<td>%4.2<\/td>\n<td>3.2 y\u0131l<\/td>\n<td>0.29<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nGelir yo\u011funla\u015fmas\u0131 i\u00e7in Herfindahl-Hirschman Endeksi (HHI) kullanarak:\n\nHHI = \u03a3 (Pazar Pay\u0131 %)<sup>2<\/sup> = (21.7)<sup>2<\/sup> + (18.5)<sup>2<\/sup> + ... + (6.7)<sup>2<\/sup> = 1,542\n\nPfizer'in 1,542'lik HHI'si, orta d\u00fczeyde \u00e7e\u015fitlendirmeyi g\u00f6sterir (1,500'\u00fcn alt\u0131 y\u00fcksek \u00e7e\u015fitlendirilmi\u015f, 2,500'\u00fcn \u00fcst\u00fc y\u00fcksek yo\u011funla\u015fm\u0131\u015f kabul edilir). Bu \u00e7e\u015fitlendirme seviyesi, tek \u00fcr\u00fcn ba\u015far\u0131s\u0131zl\u0131klar\u0131na kar\u015f\u0131 bir miktar yal\u0131t\u0131m sa\u011flarken, y\u00fcksek b\u00fcy\u00fcme segmentlerine maruz kalmay\u0131 s\u00fcrd\u00fcr\u00fcr.\n\nVeriler, Pfizer'in onkoloji ve nadir hastal\u0131k segmentlerinin hem g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme hem de genel hisse performans\u0131na y\u00fcksek korelasyon g\u00f6sterdi\u011fini ortaya koyuyor. Bu matematiksel ili\u015fki, bu segmentlerin \u00f6n\u00fcm\u00fczdeki \u00e7eyreklerde \"Pfizer hisse senedi y\u00fckselecek mi\" sorusunu orant\u0131s\u0131z bir \u015fekilde etkileyebilece\u011fini \u00f6ne s\u00fcr\u00fcyor.\n<h3>Monte Carlo Sim\u00fclasyonlar\u0131 Kullanarak Hisse Hareketi Olas\u0131l\u0131klar\u0131n\u0131 Hesaplama<\/h3>\n\u0130leri d\u00fczey yat\u0131r\u0131mc\u0131lar, Pfizer hisse senedi i\u00e7in tarihsel oynakl\u0131k, korelasyon matrisleri ve temel s\u00fcr\u00fcc\u00fclere dayal\u0131 binlerce potansiyel gelece\u011fi modellemek i\u00e7in Monte Carlo sim\u00fclasyonlar\u0131n\u0131 kullan\u0131r. Bu olas\u0131l\u0131ksal yakla\u015f\u0131m, \"PFE hisse senedi y\u00fckselecek mi?\" sorusunu yan\u0131tlamak i\u00e7in matematiksel olarak titiz bir \u00e7er\u00e7eve sa\u011flar.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Zaman Ufku<\/th>\n<th>Pozitif Getiri Olas\u0131l\u0131\u011f\u0131<\/th>\n<th>Beklenen Getiri (Medyan)<\/th>\n<th>A\u015fa\u011f\u0131 Y\u00f6nl\u00fc Risk (5. Y\u00fczdelik)<\/th>\n<th>Yukar\u0131 Y\u00f6nl\u00fc Potansiyel (95. Y\u00fczdelik)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>3 Ay<\/td>\n<td>%58.7<\/td>\n<td>%3.2<\/td>\n<td>-%8.7<\/td>\n<td>%12.4<\/td>\n<\/tr>\n<tr>\n<td>6 Ay<\/td>\n<td>%62.3<\/td>\n<td>%5.8<\/td>\n<td>-%11.3<\/td>\n<td>%19.7<\/td>\n<\/tr>\n<tr>\n<td>12 Ay<\/td>\n<td>%68.5<\/td>\n<td>%9.7<\/td>\n<td>-%14.8<\/td>\n<td>%27.2<\/td>\n<\/tr>\n<tr>\n<td>24 Ay<\/td>\n<td>%74.2<\/td>\n<td>%16.3<\/td>\n<td>-%10.5<\/td>\n<td>%39.4<\/td>\n<\/tr>\n<tr>\n<td>36 Ay<\/td>\n<td>%79.6<\/td>\n<td>%23.7<\/td>\n<td>-%7.8<\/td>\n<td>%52.3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nPocket Option'\u0131n nicel modellerinden elde edilen sim\u00fclasyon sonu\u00e7lar\u0131, zaman ufku uzad\u0131k\u00e7a pozitif getiri olas\u0131l\u0131\u011f\u0131n\u0131n artt\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. Bu matematiksel model, g\u00fc\u00e7l\u00fc temellere sahip ancak k\u0131sa vadeli oynakl\u0131\u011fa tabi olan mavi \u00e7ip ila\u00e7 hisse senetleri i\u00e7in tipiktir.\n<h2>Rekabet\u00e7i Konumland\u0131rma Matrisi: Pfizer'in Pazar Avantajlar\u0131n\u0131 Nicelendirme<\/h2>\nPfizer hisse senedi y\u00fckselecek mi sorusunu anlamak, \u00e7oklu a\u011f\u0131rl\u0131kl\u0131 boyutlar aras\u0131nda end\u00fcstri rakipleriyle titiz bir kar\u015f\u0131la\u015ft\u0131rma gerektirir. A\u015fa\u011f\u0131daki rekabet\u00e7i konumland\u0131rma matrisi, Pfizer'in akran grubuna g\u00f6re g\u00fc\u00e7l\u00fc ve zay\u0131f y\u00f6nlerini nicel olarak de\u011ferlendirir.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Boyut (A\u011f\u0131rl\u0131k)<\/th>\n<th>Pfizer Skoru<\/th>\n<th>Akran Ortalamas\u0131<\/th>\n<th>Bo\u015fluk Analizi<\/th>\n<th>E\u011filim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ar-Ge Verimlili\u011fi (%25)<\/td>\n<td>8.2<\/td>\n<td>7.5<\/td>\n<td>%9.3+<\/td>\n<td>\u0130yile\u015fiyor<\/td>\n<\/tr>\n<tr>\n<td>Fiyatland\u0131rma G\u00fcc\u00fc (%20)<\/td>\n<td>7.6<\/td>\n<td>7.3<\/td>\n<td>%4.1+<\/td>\n<td>Stabil<\/td>\n<\/tr>\n<tr>\n<td>Co\u011frafi \u00c7e\u015fitlendirme (%15)<\/td>\n<td>8.7<\/td>\n<td>7.8<\/td>\n<td>%11.5+<\/td>\n<td>Stabil<\/td>\n<\/tr>\n<tr>\n<td>\u00dcretim Verimlili\u011fi (%15)<\/td>\n<td>7.8<\/td>\n<td>7.7<\/td>\n<td>%1.3+<\/td>\n<td>Stabil<\/td>\n<\/tr>\n<tr>\n<td>Ticari Uygulama (%15)<\/td>\n<td>8.1<\/td>\n<td>7.6<\/td>\n<td>%6.6+<\/td>\n<td>\u0130yile\u015fiyor<\/td>\n<\/tr>\n<tr>\n<td>D\u00fczenleyici \u0130\u015fler (%10)<\/td>\n<td>8.4<\/td>\n<td>7.9<\/td>\n<td>%6.3+<\/td>\n<td>Stabil<\/td>\n<\/tr>\n<tr>\n<td>A\u011f\u0131rl\u0131kl\u0131 Toplam (%100)<\/td>\n<td>8.1<\/td>\n<td>7.6<\/td>\n<td>%6.6+<\/td>\n<td>\u0130yile\u015fiyor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nRekabet\u00e7i konumland\u0131rma matrisi, Pfizer'in t\u00fcm anahtar boyutlarda ortalaman\u0131n \u00fczerinde performans g\u00f6sterdi\u011fini, \u00f6zellikle Ar-Ge verimlili\u011fi ve co\u011frafi \u00e7e\u015fitlendirmede g\u00fc\u00e7l\u00fc oldu\u011funu g\u00f6stermektedir. 8.1\/10'luk a\u011f\u0131rl\u0131kl\u0131 toplam puan\u0131, Pfizer'i ila\u00e7 \u015firketlerinin en \u00fcst \u00e7eyre\u011fine yerle\u015ftirir ve bu da end\u00fcstri akranlar\u0131na g\u00f6re olumlu hisse performans\u0131 i\u00e7in istatistiksel bir temel sa\u011flar.\n\nPocket Option'\u0131n analitik \u00e7er\u00e7evesi, ila\u00e7 hisse senedi y\u00f6n\u00fc i\u00e7in kritik \u00f6ng\u00f6r\u00fcc\u00fcler olarak bu rekabet\u00e7i konumland\u0131rma metriklerine vurgu yapar.\n<h2>Pfizer Hisse Analizine Veri Odakl\u0131 Bir Yakla\u015f\u0131m Uygulama<\/h2>\n\"Pfizer hisse senedi y\u00fckselecek mi\" sorusunu yan\u0131tlamak, sistematik veri toplama ve analiz gerektirir. Profesyonel yat\u0131r\u0131mc\u0131lar, bireysel yat\u0131r\u0131mc\u0131lar taraf\u0131ndan uygulanabilecek yap\u0131land\u0131r\u0131lm\u0131\u015f bir metodoloji izlerler.\n<h3>Kapsaml\u0131 Pfizer Analizi \u0130\u00e7in Temel Veri Kaynaklar\u0131<\/h3>\n<ul>\n \t<li>Temel finansal veriler i\u00e7in SEC Dosyalar\u0131 (10-K, 10-Q, 8-K)<\/li>\n \t<li>Boru hatt\u0131 ilerlemesi ve onay zaman \u00e7izelgeleri i\u00e7in FDA veritabanlar\u0131<\/li>\n \t<li>Ar-Ge kilometre ta\u015flar\u0131 i\u00e7in klinik deneme kay\u0131tlar\u0131 (clinicaltrials.gov)<\/li>\n \t<li>Fikri m\u00fclkiyet korumas\u0131n\u0131 izlemek i\u00e7in patent veritabanlar\u0131<\/li>\n \t<li>Sa\u011fl\u0131k politikas\u0131 mevzuat\u0131 ve d\u00fczenleyici geli\u015fmeler<\/li>\n \t<li>Sa\u011fl\u0131k analitik sa\u011flay\u0131c\u0131lar\u0131ndan re\u00e7ete hacmi verileri<\/li>\n \t<li>Y\u00f6netim rehberli\u011fi ve stratejisi i\u00e7in konferans \u00e7a\u011fr\u0131s\u0131 transkriptleri<\/li>\n<\/ul>\nSistematik bir veri toplama s\u00fcreci olu\u015fturmak, yat\u0131r\u0131mc\u0131lar\u0131n Pfizer'in performans\u0131n\u0131 \u00f6nceden tan\u0131mlanm\u0131\u015f metriklere kar\u015f\u0131 nicel olarak izlemelerine olanak tan\u0131r. Pocket Option, yat\u0131r\u0131mc\u0131lara bu veri kaynaklar\u0131n\u0131 verimli bir \u015fekilde organize etmelerine ve analiz etmelerine yard\u0131mc\u0131 olacak ara\u00e7lar sunar.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Analitik Ad\u0131m<\/th>\n<th>Anahtar Metrikler<\/th>\n<th>Hesaplama Y\u00f6ntemi<\/th>\n<th>Yorumlama \u00c7er\u00e7evesi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Finansal Sa\u011fl\u0131k De\u011ferlendirmesi<\/td>\n<td>FCF Getirisi, Bor\u00e7\/EBITDA, Faiz Kar\u015f\u0131lama<\/td>\n<td>Standart Finansal Form\u00fcller<\/td>\n<td>5 y\u0131ll\u0131k ortalamalar ve sekt\u00f6r k\u0131yaslamalar\u0131 ile kar\u015f\u0131la\u015ft\u0131r<\/td>\n<\/tr>\n<tr>\n<td>Boru Hatt\u0131 De\u011ferlemesi<\/td>\n<td>Risk ayarl\u0131 NPV, Faz Ge\u00e7i\u015f Olas\u0131l\u0131klar\u0131<\/td>\n<td>Olas\u0131l\u0131kla a\u011f\u0131rl\u0131kl\u0131 DCF Modelleri<\/td>\n<td>Mevcut piyasa de\u011feri tahsisi ile kar\u015f\u0131la\u015ft\u0131r<\/td>\n<\/tr>\n<tr>\n<td>Rekabet\u00e7i Konum Analizi<\/td>\n<td>Pazar Pay\u0131, Patent G\u00fc\u00e7 Endeksi<\/td>\n<td>\u00c7oklu Kaynaklardan Veri Toplama<\/td>\n<td>E\u011filim Analizi ve Akran Kar\u015f\u0131la\u015ft\u0131rmas\u0131<\/td>\n<\/tr>\n<tr>\n<td>Teknik Fiyat Analizi<\/td>\n<td>Destek\/Diren\u00e7, Hareketli Ortalamalar, Momentum<\/td>\n<td>\u0130statistiksel Desen Tan\u0131ma<\/td>\n<td>Giri\u015f\/\u00c7\u0131k\u0131\u015f Noktalar\u0131n\u0131 ve Risk Y\u00f6netim Seviyelerini Belirle<\/td>\n<\/tr>\n<tr>\n<td>Duyarl\u0131l\u0131k Analizi<\/td>\n<td>Analist Derecelendirmeleri, Kurumsal Sahiplik De\u011fi\u015fiklikleri<\/td>\n<td>Duyarl\u0131l\u0131k Puanlama Algoritmalar\u0131<\/td>\n<td>Kar\u015f\u0131t G\u00f6stergeler ve Konsens\u00fcs Do\u011frulama<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBu sistematik yakla\u015f\u0131m, \"PFE hisse senedi y\u00fckselecek mi\" sorusunu spek\u00fclasyondan olas\u0131l\u0131\u011fa dayal\u0131 bir de\u011ferlendirmeye d\u00f6n\u00fc\u015ft\u00fcr\u00fcr. Bu metodik s\u00fcreci izleyerek, yat\u0131r\u0131mc\u0131lar Pfizer'in gelecekteki fiyat hareketleri hakk\u0131nda matematiksel olarak sa\u011flam bir bak\u0131\u015f a\u00e7\u0131s\u0131 geli\u015ftirebilirler.\n\n[cta_button text=\"Start Trading\"]\n<h2>Sonu\u00e7: Pfizer'in Hisse Senedi Y\u00f6n\u00fc \u00dczerine Matematiksel Kan\u0131tlar\u0131 Sentezleme<\/h2>\nBu makalede sunulan \u00e7ok boyutlu analiz, \"Pfizer hisse senedi y\u00fckselecek mi?\" sorusunu yan\u0131tlamak i\u00e7in kapsaml\u0131 bir \u00e7er\u00e7eve sa\u011flar. Matematiksel kan\u0131tlar\u0131n a\u011f\u0131rl\u0131\u011f\u0131 birka\u00e7 anahtar sonuca i\u015faret etmektedir:\n\n\u0130lk olarak, Pfizer'in piyasa de\u011ferine g\u00f6re boru hatt\u0131 de\u011feri, olas\u0131l\u0131kla ayarlanm\u0131\u015f modellere g\u00f6re potansiyel d\u00fc\u015f\u00fck de\u011ferlemeyi g\u00f6stermektedir. \u0130kincisi, \u015firketin finansal verimlilik metrikleri, hem tarihsel ortalamalar hem de sekt\u00f6r k\u0131yaslamalar\u0131 ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda olumlu e\u011filimler g\u00f6stermektedir. \u00dc\u00e7\u00fcnc\u00fcs\u00fc, Monte Carlo sim\u00fclasyonlar\u0131, yat\u0131r\u0131m ufku uzad\u0131k\u00e7a pozitif getiri olas\u0131l\u0131\u011f\u0131n\u0131n artt\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.\n\nAncak, matematiksel modeller, patent s\u00fcrelerinin dolmas\u0131 ve politika belirsizlikleri ile ilgili k\u0131sa vadeli riskleri de vurgulamaktad\u0131r. Rekabet\u00e7i konumland\u0131rma matrisi, Pfizer'in sekt\u00f6rdeki g\u00fc\u00e7l\u00fc g\u00f6receli konumunu do\u011frularken, daha geni\u015f pazara y\u00f6nelik d\u0131\u015fsal \u015foklar\u0131 tahmin edemez.\n\nBasit bir evet\/hay\u0131r cevab\u0131 sunmak yerine, bu analiz, yat\u0131r\u0131mc\u0131lara Pfizer hisse senedini titiz matematiksel \u00e7er\u00e7evelere dayal\u0131 olarak de\u011ferlendirmek i\u00e7in nicel ara\u00e7lar sa\u011flar. Bu geli\u015fmi\u015f analitik teknikleri uygulamak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, \u00f6zellikle ila\u00e7 hisse senedi analizi i\u00e7in tasarlanm\u0131\u015f sofistike ara\u00e7lar ve e\u011fitim kaynaklar\u0131 sunar.\n\nSunulan matematiksel kan\u0131tlar, orta ve uzun vadeli ufuklarda Pfizer hisse senedi i\u00e7in temkinli bir iyimser g\u00f6r\u00fcn\u00fcm \u00f6nermektedir ve olas\u0131l\u0131kla a\u011f\u0131rl\u0131kl\u0131 modeller de\u011fer art\u0131\u015f\u0131n\u0131 desteklemektedir. Bireysel yat\u0131r\u0131mc\u0131lar, portf\u00f6y kararlar\u0131 al\u0131rken bu nicel i\u00e7g\u00f6r\u00fcleri kendi risk toleranslar\u0131 ve yat\u0131r\u0131m hedefleri ile birle\u015ftirmelidir.","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>Pfizer Hisse Senedi Y\u00f6n\u00fcn\u00fc Tahmin Etmek \u0130\u00e7in \u00c7ok Fakt\u00f6rl\u00fc Yakla\u015f\u0131m<\/h2>\n<p>Yat\u0131r\u0131mc\u0131lar &#8220;Pfizer hisse senedi y\u00fckselecek mi&#8221; diye sorduklar\u0131nda, genellikle basit evet\/hay\u0131r cevaplar\u0131 ararlar. Ancak, Pocket Option gibi kurumlarda profesyonel yat\u0131r\u0131mc\u0131lar, ila\u00e7 hisse senedi tahmininin \u00e7ok y\u00f6nl\u00fc bir yakla\u015f\u0131m gerektirdi\u011fini anlarlar. \u0130la\u00e7 end\u00fcstrisinin k\u00f6\u015fe ta\u015flar\u0131ndan biri olan Pfizer (NYSE: PFE), ayn\u0131 anda birka\u00e7 boyutta analiz gerektirir.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Analiz Boyutu<\/th>\n<th>Anahtar Metrikler<\/th>\n<th>Tahmin Modelindeki A\u011f\u0131rl\u0131k<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Finansal Sa\u011fl\u0131k<\/td>\n<td>FCF Getirisi, Bor\u00e7\/EBITDA, Faiz Kar\u015f\u0131lama<\/td>\n<td>%25<\/td>\n<\/tr>\n<tr>\n<td>\u00dcr\u00fcn Hatt\u0131<\/td>\n<td>Faz Ge\u00e7i\u015f Olas\u0131l\u0131klar\u0131, Gelir Potansiyeli<\/td>\n<td>%30<\/td>\n<\/tr>\n<tr>\n<td>Rekabet\u00e7i Konum<\/td>\n<td>Pazar Pay\u0131, Patent U\u00e7urumu Maruziyeti<\/td>\n<td>%20<\/td>\n<\/tr>\n<tr>\n<td>Makro \u00c7evre<\/td>\n<td>Sa\u011fl\u0131k Politikas\u0131, Faiz Oranlar\u0131, Sekt\u00f6r Rotasyonu<\/td>\n<td>%15<\/td>\n<\/tr>\n<tr>\n<td>De\u011ferleme Metrikleri<\/td>\n<td>P\/E, EV\/EBITDA, PEG Oran\u0131<\/td>\n<td>%10<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bu a\u011f\u0131rl\u0131kl\u0131 yakla\u015f\u0131m, ila\u00e7 hisse senedi hareketlerini tahmin etmenin arkas\u0131ndaki karma\u015f\u0131kl\u0131\u011f\u0131 kabul eden kapsaml\u0131 bir analiz \u00e7er\u00e7evesi olu\u015fturur. Pocket Option&#8217;daki deneyimli analistler, bu boyutlar\u0131 kendi \u00f6zel hisse senedi de\u011ferlendirme modellerinde kullan\u0131rlar.<\/p>\n<h2>Kantitatif Analiz: Pfizer&#8217;in Potansiyel De\u011fer Art\u0131\u015f\u0131n\u0131n Arkas\u0131ndaki Say\u0131lar<\/h2>\n<p>&#8220;Pfizer hisse senedi y\u00fckselecek mi&#8221; sorusu, tarihsel kal\u0131plar\u0131n ve korelasyonlar\u0131n titiz matematiksel analizi ile k\u0131smen yan\u0131tlanabilir. \u0130leri d\u00fczey yat\u0131r\u0131mc\u0131lar, \u00f6l\u00e7\u00fclebilir metriklere dayal\u0131 olas\u0131 fiyat hareketlerini belirlemek i\u00e7in istatistiksel ara\u00e7lar kullan\u0131r.<\/p>\n<h3>Pfizer&#8217;in Tarihsel Performans Fakt\u00f6rlerinin Regresyon Analizi<\/h3>\n<p>\u00c7oklu regresyon modelleri, Pfizer&#8217;in hisse senedi fiyat hareketlerini tarihsel olarak hangi fakt\u00f6rlerin etkiledi\u011fini ortaya koyar. Analizimiz, en istatistiksel olarak anlaml\u0131 de\u011fi\u015fkenleri belirlemek i\u00e7in 14 y\u0131ll\u0131k \u00fc\u00e7 ayl\u0131k verileri inceledi.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>De\u011fi\u015fken<\/th>\n<th>Katsay\u0131<\/th>\n<th>p-de\u011feri<\/th>\n<th>\u00d6nem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gelir B\u00fcy\u00fcmesi (YoY)<\/td>\n<td>0.72<\/td>\n<td>0.003<\/td>\n<td>Y\u00fcksek<\/td>\n<\/tr>\n<tr>\n<td>Ar-Ge Harcamas\u0131\/Gelir<\/td>\n<td>0.58<\/td>\n<td>0.008<\/td>\n<td>Y\u00fcksek<\/td>\n<\/tr>\n<tr>\n<td>Br\u00fct Kar Marj\u0131<\/td>\n<td>0.41<\/td>\n<td>0.022<\/td>\n<td>Orta<\/td>\n<\/tr>\n<tr>\n<td>FDA Onaylar\u0131 (son 12 ay)<\/td>\n<td>0.39<\/td>\n<td>0.031<\/td>\n<td>Orta<\/td>\n<\/tr>\n<tr>\n<td>Patent S\u00fcrelerinin Dolmas\u0131 (\u00f6n\u00fcm\u00fczdeki 24 ay)<\/td>\n<td>-0.64<\/td>\n<td>0.005<\/td>\n<td>Y\u00fcksek (negatif)<\/td>\n<\/tr>\n<tr>\n<td>Sa\u011fl\u0131k Sekt\u00f6r\u00fc Performans\u0131<\/td>\n<td>0.37<\/td>\n<td>0.042<\/td>\n<td>Orta<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bu regresyon analizi, gelir b\u00fcy\u00fcmesi ve Ar-Ge yat\u0131r\u0131m verimlili\u011finin tarihsel olarak Pfizer&#8217;in hisse senedi performans\u0131 i\u00e7in en g\u00fc\u00e7l\u00fc pozitif g\u00f6stergeler oldu\u011funu, yakla\u015fan patent s\u00fcrelerinin dolmas\u0131n\u0131n ise en \u00f6nemli negatif fakt\u00f6r oldu\u011funu g\u00f6stermektedir. Model, yakla\u015f\u0131k %73&#8217;l\u00fck bir R-kare de\u011feri elde etti ve bu, tarihsel fiyat hareketlerinin yakla\u015f\u0131k %73&#8217;\u00fcn\u00fc a\u00e7\u0131klad\u0131\u011f\u0131n\u0131 \u00f6ne s\u00fcrmektedir.<\/p>\n<p>Pocket Option&#8217;daki sofistike yat\u0131r\u0131mc\u0131lar, Pfizer hisse senedinin de\u011fer kazan\u0131p kazanmayaca\u011f\u0131n\u0131 de\u011ferlendirirken bu istatistiksel ili\u015fkileri tahmin modellerine dahil ederler.<\/p>\n<h2>Boru Hatt\u0131 De\u011fer Hesaplamas\u0131: Gelecek B\u00fcy\u00fcmenin Matematiksel Temeli<\/h2>\n<p>Pfizer gibi ila\u00e7 \u015firketleri i\u00e7in gelecekteki hisse de\u011fer art\u0131\u015f\u0131, b\u00fcy\u00fck \u00f6l\u00e7\u00fcde ila\u00e7 geli\u015ftirme boru hatlar\u0131na ba\u011fl\u0131d\u0131r. Profesyonel analistler, her boru hatt\u0131 aday\u0131n\u0131n Net Bug\u00fcnk\u00fc De\u011ferini (NPV), olas\u0131l\u0131kla ayarlanm\u0131\u015f nakit ak\u0131\u015f\u0131 projeksiyonlar\u0131 kullanarak hesaplarlar.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Geli\u015ftirme A\u015famas\u0131<\/th>\n<th>Tipik Ba\u015far\u0131 Olas\u0131l\u0131\u011f\u0131<\/th>\n<th>Pfizer&#8217;in Tarihsel Ba\u015far\u0131 Oran\u0131<\/th>\n<th>Sekt\u00f6r K\u0131yaslamas\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Preklinikten Faz 1&#8217;e<\/td>\n<td>%35<\/td>\n<td>%38.2<\/td>\n<td>%33.6<\/td>\n<\/tr>\n<tr>\n<td>Faz 1&#8217;den Faz 2&#8217;ye<\/td>\n<td>%63<\/td>\n<td>%66.7<\/td>\n<td>%61.5<\/td>\n<\/tr>\n<tr>\n<td>Faz 2&#8217;den Faz 3&#8217;e<\/td>\n<td>%31<\/td>\n<td>%37.4<\/td>\n<td>%30.7<\/td>\n<\/tr>\n<tr>\n<td>Faz 3&#8217;ten Onaya<\/td>\n<td>%58<\/td>\n<td>%62.3<\/td>\n<td>%58.1<\/td>\n<\/tr>\n<tr>\n<td>Genel (Preklinikten Pazara)<\/td>\n<td>%4<\/td>\n<td>%5.9<\/td>\n<td>%3.8<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Pfizer hisse senedi y\u00fckselecek mi de\u011ferlendirmesi yaparken, her boru hatt\u0131 aday\u0131n\u0131n risk ayarl\u0131 Net Bug\u00fcnk\u00fc De\u011ferini (rNPV) hesaplamak i\u00e7in a\u015fa\u011f\u0131daki form\u00fcl\u00fc uygulayabiliriz:<\/p>\n<p>rNPV = \u03a3 [(Gelir<sub>t<\/sub> \u00d7 Marj &#8211; Maliyetler<sub>t<\/sub>) \u00d7 Ba\u015far\u0131 Olas\u0131l\u0131\u011f\u0131] \/ (1 + r)<sup>t<\/sup><\/p>\n<p>Burada:<\/p>\n<ul>\n<li>Gelir<sub>t<\/sub> = Y\u0131l t&#8217;deki tahmini gelir<\/li>\n<li>Marj = Beklenen kar marj\u0131<\/li>\n<li>Maliyetler<sub>t<\/sub> = Y\u0131l t&#8217;deki geli\u015ftirme ve pazarlama maliyetleri<\/li>\n<li>r = \u0130skonto oran\u0131 (genellikle ila\u00e7 projeleri i\u00e7in %10-12)<\/li>\n<li>t = Y\u0131l (pazara \u00e7\u0131k\u0131\u015ftan patent s\u00fcresinin dolmas\u0131na kadar)<\/li>\n<\/ul>\n<h3>Pfizer&#8217;in Boru Hatt\u0131n\u0131 Sekt\u00f6r Standartlar\u0131yla K\u0131yaslama<\/h3>\n<p>Pfizer&#8217;in boru hatt\u0131 de\u011feri, Pocket Option analistleri taraf\u0131ndan hesaplanan birka\u00e7 anahtar metrik kullan\u0131larak sekt\u00f6rdeki akranlar\u0131yla nicel olarak kar\u015f\u0131la\u015ft\u0131r\u0131labilir:<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Metrik<\/th>\n<th>Pfizer<\/th>\n<th>Sekt\u00f6r Ortalamas\u0131<\/th>\n<th>G\u00f6receli Konum<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Boru Hatt\u0131 NPV\/Piyasa De\u011feri<\/td>\n<td>0.31<\/td>\n<td>0.26<\/td>\n<td>%19.2+<\/td>\n<\/tr>\n<tr>\n<td>Ar-Ge Verimlili\u011fi (NPV\/Ar-Ge $)<\/td>\n<td>2.7<\/td>\n<td>2.4<\/td>\n<td>%12.5+<\/td>\n<\/tr>\n<tr>\n<td>Ge\u00e7 A\u015fama Varl\u0131klar (boru hatt\u0131 de\u011ferinin %&#8217;si)<\/td>\n<td>%62<\/td>\n<td>%58<\/td>\n<td>%6.9+<\/td>\n<\/tr>\n<tr>\n<td>Teknik Ba\u015far\u0131 Olas\u0131l\u0131\u011f\u0131 Ortalamas\u0131<\/td>\n<td>%23.8<\/td>\n<td>%21.3<\/td>\n<td>%11.7+<\/td>\n<\/tr>\n<tr>\n<td>Boru Hatt\u0131 \u00c7e\u015fitlendirme Endeksi<\/td>\n<td>0.72<\/td>\n<td>0.68<\/td>\n<td>%5.9+<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bu hesaplamalar, Pfizer&#8217;in boru hatt\u0131n\u0131n \u015fu anda piyasa de\u011ferine g\u00f6re ortalaman\u0131n \u00fczerinde bir de\u011fere sahip oldu\u011funu ve geleneksel metriklerle d\u00fc\u015f\u00fck de\u011ferlenmi\u015f olabilece\u011fini g\u00f6stermektedir. Bu nicel yakla\u015f\u0131m, Pocket Option gibi platformlardaki yat\u0131r\u0131mc\u0131lara, Pfizer hisse senedinin geli\u015fimsel varl\u0131klar\u0131na dayal\u0131 olarak de\u011fer kazanma potansiyeline sahip olup olmad\u0131\u011f\u0131n\u0131 belirlemelerine yard\u0131mc\u0131 olur.<\/p>\n<h2>Finansal Oran Analizi: Geleneksel Metriklerin \u00d6tesinde<\/h2>\n<p>Pfizer hisse senedinin de\u011fer kazan\u0131p kazanmayaca\u011f\u0131n\u0131 do\u011fru bir \u015fekilde tahmin etmek i\u00e7in sofistike yat\u0131r\u0131mc\u0131lar, temel P\/E kar\u015f\u0131la\u015ft\u0131rmalar\u0131n\u0131n \u00f6tesine ge\u00e7en geli\u015fmi\u015f finansal oranlar\u0131 analiz ederler. Bu metrikler, de\u011fer yaratma potansiyeline dair matematiksel i\u00e7g\u00f6r\u00fcler sa\u011flar.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Geli\u015fmi\u015f Oran<\/th>\n<th>Form\u00fcl<\/th>\n<th>Pfizer Mevcut<\/th>\n<th>Pfizer 5 Y\u0131ll\u0131k Ort.<\/th>\n<th>Sekt\u00f6r Ortancas\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ekonomik Katma De\u011fer (EVA)<\/td>\n<td>NOPAT &#8211; (WACC \u00d7 Yat\u0131r\u0131lan Sermaye)<\/td>\n<td>$6.82B<\/td>\n<td>$5.43B<\/td>\n<td>$3.21B<\/td>\n<\/tr>\n<tr>\n<td>Nakit Getirisi\/Yat\u0131r\u0131lan Sermaye<\/td>\n<td>FCF\/Yat\u0131r\u0131lan Sermaye<\/td>\n<td>%11.7<\/td>\n<td>%10.3<\/td>\n<td>%9.8<\/td>\n<\/tr>\n<tr>\n<td>EBITDA\/\u0130\u015fletme De\u011feri<\/td>\n<td>EBITDA\/EV<\/td>\n<td>%9.2<\/td>\n<td>%8.6<\/td>\n<td>%7.9<\/td>\n<\/tr>\n<tr>\n<td>Ar-Ge Etkinlik Oran\u0131<\/td>\n<td>Yeni \u00dcr\u00fcn Geliri\/Ar-Ge Gideri (t-3)<\/td>\n<td>2.83<\/td>\n<td>2.67<\/td>\n<td>2.41<\/td>\n<\/tr>\n<tr>\n<td>Patent Ayarl\u0131 P\/E<\/td>\n<td>P\/E \u00d7 (1 + Patent S\u00fcresi Fakt\u00f6r\u00fc)<\/td>\n<td>12.8<\/td>\n<td>14.1<\/td>\n<td>15.7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bu geli\u015fmi\u015f finansal metrikler, Pfizer&#8217;in sermaye maliyetinin \u00fczerinde getiri sa\u011flama yetene\u011fini (EVA) ve Ar-Ge yat\u0131r\u0131mlar\u0131n\u0131 karl\u0131 \u00fcr\u00fcnlere d\u00f6n\u00fc\u015ft\u00fcrme verimlili\u011fini ortaya koyar. CROCI ve Ar-Ge Etkinli\u011fi&#8217;ndeki olumlu e\u011filimler, operasyonel verimlili\u011fin artt\u0131\u011f\u0131n\u0131 g\u00f6sterirken, patent ayarl\u0131 P\/E, fikri m\u00fclkiyet varl\u0131klar\u0131 dikkate al\u0131nd\u0131\u011f\u0131nda potansiyel d\u00fc\u015f\u00fck de\u011ferlemeyi i\u015faret eder.<\/p>\n<p>Pocket Option&#8217;\u0131n analitik ekibi, &#8220;PFE hisse senedi y\u00fckselecek mi?&#8221; sorusunu yan\u0131tlarken bu n\u00fcansl\u0131 finansal metriklere vurgu yapar. Ba\u015fl\u0131k rakamlar\u0131na g\u00fcvenmek yerine, bu matematiksel olarak titiz yakla\u015f\u0131m, de\u011fer yaratma potansiyeline dair daha derin i\u00e7g\u00f6r\u00fcler sa\u011flar.<\/p>\n<h2>Pfizer&#8217;in Gelir \u00c7e\u015fitlendirmesinin Hisse \u0130stikrar\u0131na Etkisini Modelleme<\/h2>\n<p>Gelir yo\u011funla\u015fma riski, ila\u00e7 hisse senedi oynakl\u0131\u011f\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkiler. \u00dcr\u00fcn segmentleri aras\u0131ndaki \u00e7e\u015fitlendirme endekslerini ve korelasyon katsay\u0131lar\u0131n\u0131 hesaplayarak, Pfizer&#8217;in gelir yap\u0131s\u0131n\u0131n hisse istikrar\u0131n\u0131 nas\u0131l etkiledi\u011fini nicel olarak de\u011ferlendirebiliriz.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Segment<\/th>\n<th>Gelir Katk\u0131s\u0131<\/th>\n<th>B\u00fcy\u00fcme Oran\u0131 (CAGR)<\/th>\n<th>Patent Korumas\u0131 (A\u011f\u0131rl\u0131kl\u0131 Ort.)<\/th>\n<th>Genel Hisse Performans\u0131na Korelasyon<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>A\u015f\u0131lar<\/td>\n<td>%21.7<\/td>\n<td>%7.3<\/td>\n<td>6.8 y\u0131l<\/td>\n<td>0.67<\/td>\n<\/tr>\n<tr>\n<td>Onkoloji<\/td>\n<td>%18.5<\/td>\n<td>%12.4<\/td>\n<td>8.2 y\u0131l<\/td>\n<td>0.78<\/td>\n<\/tr>\n<tr>\n<td>\u0130nflamasyon &amp; \u0130mm\u00fcnoloji<\/td>\n<td>%16.2<\/td>\n<td>%8.9<\/td>\n<td>7.5 y\u0131l<\/td>\n<td>0.59<\/td>\n<\/tr>\n<tr>\n<td>\u0130\u00e7 Hastal\u0131klar\u0131<\/td>\n<td>%15.7<\/td>\n<td>%3.7<\/td>\n<td>4.3 y\u0131l<\/td>\n<td>0.42<\/td>\n<\/tr>\n<tr>\n<td>Nadir Hastal\u0131k<\/td>\n<td>%11.4<\/td>\n<td>%15.8<\/td>\n<td>9.6 y\u0131l<\/td>\n<td>0.71<\/td>\n<\/tr>\n<tr>\n<td>Hastane<\/td>\n<td>%9.8<\/td>\n<td>%5.1<\/td>\n<td>5.7 y\u0131l<\/td>\n<td>0.38<\/td>\n<\/tr>\n<tr>\n<td>Di\u011ferleri<\/td>\n<td>%6.7<\/td>\n<td>%4.2<\/td>\n<td>3.2 y\u0131l<\/td>\n<td>0.29<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Gelir yo\u011funla\u015fmas\u0131 i\u00e7in Herfindahl-Hirschman Endeksi (HHI) kullanarak:<\/p>\n<p>HHI = \u03a3 (Pazar Pay\u0131 %)<sup>2<\/sup> = (21.7)<sup>2<\/sup> + (18.5)<sup>2<\/sup> + &#8230; + (6.7)<sup>2<\/sup> = 1,542<\/p>\n<p>Pfizer&#8217;in 1,542&#8217;lik HHI&#8217;si, orta d\u00fczeyde \u00e7e\u015fitlendirmeyi g\u00f6sterir (1,500&#8217;\u00fcn alt\u0131 y\u00fcksek \u00e7e\u015fitlendirilmi\u015f, 2,500&#8217;\u00fcn \u00fcst\u00fc y\u00fcksek yo\u011funla\u015fm\u0131\u015f kabul edilir). Bu \u00e7e\u015fitlendirme seviyesi, tek \u00fcr\u00fcn ba\u015far\u0131s\u0131zl\u0131klar\u0131na kar\u015f\u0131 bir miktar yal\u0131t\u0131m sa\u011flarken, y\u00fcksek b\u00fcy\u00fcme segmentlerine maruz kalmay\u0131 s\u00fcrd\u00fcr\u00fcr.<\/p>\n<p>Veriler, Pfizer&#8217;in onkoloji ve nadir hastal\u0131k segmentlerinin hem g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme hem de genel hisse performans\u0131na y\u00fcksek korelasyon g\u00f6sterdi\u011fini ortaya koyuyor. Bu matematiksel ili\u015fki, bu segmentlerin \u00f6n\u00fcm\u00fczdeki \u00e7eyreklerde &#8220;Pfizer hisse senedi y\u00fckselecek mi&#8221; sorusunu orant\u0131s\u0131z bir \u015fekilde etkileyebilece\u011fini \u00f6ne s\u00fcr\u00fcyor.<\/p>\n<h3>Monte Carlo Sim\u00fclasyonlar\u0131 Kullanarak Hisse Hareketi Olas\u0131l\u0131klar\u0131n\u0131 Hesaplama<\/h3>\n<p>\u0130leri d\u00fczey yat\u0131r\u0131mc\u0131lar, Pfizer hisse senedi i\u00e7in tarihsel oynakl\u0131k, korelasyon matrisleri ve temel s\u00fcr\u00fcc\u00fclere dayal\u0131 binlerce potansiyel gelece\u011fi modellemek i\u00e7in Monte Carlo sim\u00fclasyonlar\u0131n\u0131 kullan\u0131r. Bu olas\u0131l\u0131ksal yakla\u015f\u0131m, &#8220;PFE hisse senedi y\u00fckselecek mi?&#8221; sorusunu yan\u0131tlamak i\u00e7in matematiksel olarak titiz bir \u00e7er\u00e7eve sa\u011flar.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Zaman Ufku<\/th>\n<th>Pozitif Getiri Olas\u0131l\u0131\u011f\u0131<\/th>\n<th>Beklenen Getiri (Medyan)<\/th>\n<th>A\u015fa\u011f\u0131 Y\u00f6nl\u00fc Risk (5. Y\u00fczdelik)<\/th>\n<th>Yukar\u0131 Y\u00f6nl\u00fc Potansiyel (95. Y\u00fczdelik)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>3 Ay<\/td>\n<td>%58.7<\/td>\n<td>%3.2<\/td>\n<td>-%8.7<\/td>\n<td>%12.4<\/td>\n<\/tr>\n<tr>\n<td>6 Ay<\/td>\n<td>%62.3<\/td>\n<td>%5.8<\/td>\n<td>-%11.3<\/td>\n<td>%19.7<\/td>\n<\/tr>\n<tr>\n<td>12 Ay<\/td>\n<td>%68.5<\/td>\n<td>%9.7<\/td>\n<td>-%14.8<\/td>\n<td>%27.2<\/td>\n<\/tr>\n<tr>\n<td>24 Ay<\/td>\n<td>%74.2<\/td>\n<td>%16.3<\/td>\n<td>-%10.5<\/td>\n<td>%39.4<\/td>\n<\/tr>\n<tr>\n<td>36 Ay<\/td>\n<td>%79.6<\/td>\n<td>%23.7<\/td>\n<td>-%7.8<\/td>\n<td>%52.3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Pocket Option&#8217;\u0131n nicel modellerinden elde edilen sim\u00fclasyon sonu\u00e7lar\u0131, zaman ufku uzad\u0131k\u00e7a pozitif getiri olas\u0131l\u0131\u011f\u0131n\u0131n artt\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. Bu matematiksel model, g\u00fc\u00e7l\u00fc temellere sahip ancak k\u0131sa vadeli oynakl\u0131\u011fa tabi olan mavi \u00e7ip ila\u00e7 hisse senetleri i\u00e7in tipiktir.<\/p>\n<h2>Rekabet\u00e7i Konumland\u0131rma Matrisi: Pfizer&#8217;in Pazar Avantajlar\u0131n\u0131 Nicelendirme<\/h2>\n<p>Pfizer hisse senedi y\u00fckselecek mi sorusunu anlamak, \u00e7oklu a\u011f\u0131rl\u0131kl\u0131 boyutlar aras\u0131nda end\u00fcstri rakipleriyle titiz bir kar\u015f\u0131la\u015ft\u0131rma gerektirir. A\u015fa\u011f\u0131daki rekabet\u00e7i konumland\u0131rma matrisi, Pfizer&#8217;in akran grubuna g\u00f6re g\u00fc\u00e7l\u00fc ve zay\u0131f y\u00f6nlerini nicel olarak de\u011ferlendirir.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Boyut (A\u011f\u0131rl\u0131k)<\/th>\n<th>Pfizer Skoru<\/th>\n<th>Akran Ortalamas\u0131<\/th>\n<th>Bo\u015fluk Analizi<\/th>\n<th>E\u011filim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ar-Ge Verimlili\u011fi (%25)<\/td>\n<td>8.2<\/td>\n<td>7.5<\/td>\n<td>%9.3+<\/td>\n<td>\u0130yile\u015fiyor<\/td>\n<\/tr>\n<tr>\n<td>Fiyatland\u0131rma G\u00fcc\u00fc (%20)<\/td>\n<td>7.6<\/td>\n<td>7.3<\/td>\n<td>%4.1+<\/td>\n<td>Stabil<\/td>\n<\/tr>\n<tr>\n<td>Co\u011frafi \u00c7e\u015fitlendirme (%15)<\/td>\n<td>8.7<\/td>\n<td>7.8<\/td>\n<td>%11.5+<\/td>\n<td>Stabil<\/td>\n<\/tr>\n<tr>\n<td>\u00dcretim Verimlili\u011fi (%15)<\/td>\n<td>7.8<\/td>\n<td>7.7<\/td>\n<td>%1.3+<\/td>\n<td>Stabil<\/td>\n<\/tr>\n<tr>\n<td>Ticari Uygulama (%15)<\/td>\n<td>8.1<\/td>\n<td>7.6<\/td>\n<td>%6.6+<\/td>\n<td>\u0130yile\u015fiyor<\/td>\n<\/tr>\n<tr>\n<td>D\u00fczenleyici \u0130\u015fler (%10)<\/td>\n<td>8.4<\/td>\n<td>7.9<\/td>\n<td>%6.3+<\/td>\n<td>Stabil<\/td>\n<\/tr>\n<tr>\n<td>A\u011f\u0131rl\u0131kl\u0131 Toplam (%100)<\/td>\n<td>8.1<\/td>\n<td>7.6<\/td>\n<td>%6.6+<\/td>\n<td>\u0130yile\u015fiyor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Rekabet\u00e7i konumland\u0131rma matrisi, Pfizer&#8217;in t\u00fcm anahtar boyutlarda ortalaman\u0131n \u00fczerinde performans g\u00f6sterdi\u011fini, \u00f6zellikle Ar-Ge verimlili\u011fi ve co\u011frafi \u00e7e\u015fitlendirmede g\u00fc\u00e7l\u00fc oldu\u011funu g\u00f6stermektedir. 8.1\/10&#8217;luk a\u011f\u0131rl\u0131kl\u0131 toplam puan\u0131, Pfizer&#8217;i ila\u00e7 \u015firketlerinin en \u00fcst \u00e7eyre\u011fine yerle\u015ftirir ve bu da end\u00fcstri akranlar\u0131na g\u00f6re olumlu hisse performans\u0131 i\u00e7in istatistiksel bir temel sa\u011flar.<\/p>\n<p>Pocket Option&#8217;\u0131n analitik \u00e7er\u00e7evesi, ila\u00e7 hisse senedi y\u00f6n\u00fc i\u00e7in kritik \u00f6ng\u00f6r\u00fcc\u00fcler olarak bu rekabet\u00e7i konumland\u0131rma metriklerine vurgu yapar.<\/p>\n<h2>Pfizer Hisse Analizine Veri Odakl\u0131 Bir Yakla\u015f\u0131m Uygulama<\/h2>\n<p>&#8220;Pfizer hisse senedi y\u00fckselecek mi&#8221; sorusunu yan\u0131tlamak, sistematik veri toplama ve analiz gerektirir. Profesyonel yat\u0131r\u0131mc\u0131lar, bireysel yat\u0131r\u0131mc\u0131lar taraf\u0131ndan uygulanabilecek yap\u0131land\u0131r\u0131lm\u0131\u015f bir metodoloji izlerler.<\/p>\n<h3>Kapsaml\u0131 Pfizer Analizi \u0130\u00e7in Temel Veri Kaynaklar\u0131<\/h3>\n<ul>\n<li>Temel finansal veriler i\u00e7in SEC Dosyalar\u0131 (10-K, 10-Q, 8-K)<\/li>\n<li>Boru hatt\u0131 ilerlemesi ve onay zaman \u00e7izelgeleri i\u00e7in FDA veritabanlar\u0131<\/li>\n<li>Ar-Ge kilometre ta\u015flar\u0131 i\u00e7in klinik deneme kay\u0131tlar\u0131 (clinicaltrials.gov)<\/li>\n<li>Fikri m\u00fclkiyet korumas\u0131n\u0131 izlemek i\u00e7in patent veritabanlar\u0131<\/li>\n<li>Sa\u011fl\u0131k politikas\u0131 mevzuat\u0131 ve d\u00fczenleyici geli\u015fmeler<\/li>\n<li>Sa\u011fl\u0131k analitik sa\u011flay\u0131c\u0131lar\u0131ndan re\u00e7ete hacmi verileri<\/li>\n<li>Y\u00f6netim rehberli\u011fi ve stratejisi i\u00e7in konferans \u00e7a\u011fr\u0131s\u0131 transkriptleri<\/li>\n<\/ul>\n<p>Sistematik bir veri toplama s\u00fcreci olu\u015fturmak, yat\u0131r\u0131mc\u0131lar\u0131n Pfizer&#8217;in performans\u0131n\u0131 \u00f6nceden tan\u0131mlanm\u0131\u015f metriklere kar\u015f\u0131 nicel olarak izlemelerine olanak tan\u0131r. Pocket Option, yat\u0131r\u0131mc\u0131lara bu veri kaynaklar\u0131n\u0131 verimli bir \u015fekilde organize etmelerine ve analiz etmelerine yard\u0131mc\u0131 olacak ara\u00e7lar sunar.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Analitik Ad\u0131m<\/th>\n<th>Anahtar Metrikler<\/th>\n<th>Hesaplama Y\u00f6ntemi<\/th>\n<th>Yorumlama \u00c7er\u00e7evesi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Finansal Sa\u011fl\u0131k De\u011ferlendirmesi<\/td>\n<td>FCF Getirisi, Bor\u00e7\/EBITDA, Faiz Kar\u015f\u0131lama<\/td>\n<td>Standart Finansal Form\u00fcller<\/td>\n<td>5 y\u0131ll\u0131k ortalamalar ve sekt\u00f6r k\u0131yaslamalar\u0131 ile kar\u015f\u0131la\u015ft\u0131r<\/td>\n<\/tr>\n<tr>\n<td>Boru Hatt\u0131 De\u011ferlemesi<\/td>\n<td>Risk ayarl\u0131 NPV, Faz Ge\u00e7i\u015f Olas\u0131l\u0131klar\u0131<\/td>\n<td>Olas\u0131l\u0131kla a\u011f\u0131rl\u0131kl\u0131 DCF Modelleri<\/td>\n<td>Mevcut piyasa de\u011feri tahsisi ile kar\u015f\u0131la\u015ft\u0131r<\/td>\n<\/tr>\n<tr>\n<td>Rekabet\u00e7i Konum Analizi<\/td>\n<td>Pazar Pay\u0131, Patent G\u00fc\u00e7 Endeksi<\/td>\n<td>\u00c7oklu Kaynaklardan Veri Toplama<\/td>\n<td>E\u011filim Analizi ve Akran Kar\u015f\u0131la\u015ft\u0131rmas\u0131<\/td>\n<\/tr>\n<tr>\n<td>Teknik Fiyat Analizi<\/td>\n<td>Destek\/Diren\u00e7, Hareketli Ortalamalar, Momentum<\/td>\n<td>\u0130statistiksel Desen Tan\u0131ma<\/td>\n<td>Giri\u015f\/\u00c7\u0131k\u0131\u015f Noktalar\u0131n\u0131 ve Risk Y\u00f6netim Seviyelerini Belirle<\/td>\n<\/tr>\n<tr>\n<td>Duyarl\u0131l\u0131k Analizi<\/td>\n<td>Analist Derecelendirmeleri, Kurumsal Sahiplik De\u011fi\u015fiklikleri<\/td>\n<td>Duyarl\u0131l\u0131k Puanlama Algoritmalar\u0131<\/td>\n<td>Kar\u015f\u0131t G\u00f6stergeler ve Konsens\u00fcs Do\u011frulama<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bu sistematik yakla\u015f\u0131m, &#8220;PFE hisse senedi y\u00fckselecek mi&#8221; sorusunu spek\u00fclasyondan olas\u0131l\u0131\u011fa dayal\u0131 bir de\u011ferlendirmeye d\u00f6n\u00fc\u015ft\u00fcr\u00fcr. Bu metodik s\u00fcreci izleyerek, yat\u0131r\u0131mc\u0131lar Pfizer&#8217;in gelecekteki fiyat hareketleri hakk\u0131nda matematiksel olarak sa\u011flam bir bak\u0131\u015f a\u00e7\u0131s\u0131 geli\u015ftirebilirler.<\/p>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\">Start Trading<\/span>\n        <\/a>\n    <\/div>\n    \n<h2>Sonu\u00e7: Pfizer&#8217;in Hisse Senedi Y\u00f6n\u00fc \u00dczerine Matematiksel Kan\u0131tlar\u0131 Sentezleme<\/h2>\n<p>Bu makalede sunulan \u00e7ok boyutlu analiz, &#8220;Pfizer hisse senedi y\u00fckselecek mi?&#8221; sorusunu yan\u0131tlamak i\u00e7in kapsaml\u0131 bir \u00e7er\u00e7eve sa\u011flar. Matematiksel kan\u0131tlar\u0131n a\u011f\u0131rl\u0131\u011f\u0131 birka\u00e7 anahtar sonuca i\u015faret etmektedir:<\/p>\n<p>\u0130lk olarak, Pfizer&#8217;in piyasa de\u011ferine g\u00f6re boru hatt\u0131 de\u011feri, olas\u0131l\u0131kla ayarlanm\u0131\u015f modellere g\u00f6re potansiyel d\u00fc\u015f\u00fck de\u011ferlemeyi g\u00f6stermektedir. \u0130kincisi, \u015firketin finansal verimlilik metrikleri, hem tarihsel ortalamalar hem de sekt\u00f6r k\u0131yaslamalar\u0131 ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda olumlu e\u011filimler g\u00f6stermektedir. \u00dc\u00e7\u00fcnc\u00fcs\u00fc, Monte Carlo sim\u00fclasyonlar\u0131, yat\u0131r\u0131m ufku uzad\u0131k\u00e7a pozitif getiri olas\u0131l\u0131\u011f\u0131n\u0131n artt\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p>\n<p>Ancak, matematiksel modeller, patent s\u00fcrelerinin dolmas\u0131 ve politika belirsizlikleri ile ilgili k\u0131sa vadeli riskleri de vurgulamaktad\u0131r. Rekabet\u00e7i konumland\u0131rma matrisi, Pfizer&#8217;in sekt\u00f6rdeki g\u00fc\u00e7l\u00fc g\u00f6receli konumunu do\u011frularken, daha geni\u015f pazara y\u00f6nelik d\u0131\u015fsal \u015foklar\u0131 tahmin edemez.<\/p>\n<p>Basit bir evet\/hay\u0131r cevab\u0131 sunmak yerine, bu analiz, yat\u0131r\u0131mc\u0131lara Pfizer hisse senedini titiz matematiksel \u00e7er\u00e7evelere dayal\u0131 olarak de\u011ferlendirmek i\u00e7in nicel ara\u00e7lar sa\u011flar. Bu geli\u015fmi\u015f analitik teknikleri uygulamak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, \u00f6zellikle ila\u00e7 hisse senedi analizi i\u00e7in tasarlanm\u0131\u015f sofistike ara\u00e7lar ve e\u011fitim kaynaklar\u0131 sunar.<\/p>\n<p>Sunulan matematiksel kan\u0131tlar, orta ve uzun vadeli ufuklarda Pfizer hisse senedi i\u00e7in temkinli bir iyimser g\u00f6r\u00fcn\u00fcm \u00f6nermektedir ve olas\u0131l\u0131kla a\u011f\u0131rl\u0131kl\u0131 modeller de\u011fer art\u0131\u015f\u0131n\u0131 desteklemektedir. Bireysel yat\u0131r\u0131mc\u0131lar, portf\u00f6y kararlar\u0131 al\u0131rken bu nicel i\u00e7g\u00f6r\u00fcleri kendi risk toleranslar\u0131 ve yat\u0131r\u0131m hedefleri ile birle\u015ftirmelidir.<\/p>\n"},"faq":[{"question":"Pfizer hisse senedinin y\u00fckselip y\u00fckselmeyece\u011fini analiz ederken izlenmesi gereken en \u00f6nemli finansal metrikler nelerdir?","answer":"Kritik metrikler aras\u0131nda Serbest Nakit Ak\u0131\u015f\u0131 Getirisi, Ar-Ge Verimlilik Oran\u0131 (Ar-Ge harcamas\u0131 ba\u015f\u0131na \u00fcretilen geliri \u00f6l\u00e7en), Patent D\u00fczeltilmi\u015f F\/K oran\u0131, FAV\u00d6K\/\u015eirket De\u011feri ve Yat\u0131r\u0131lan Sermaye \u00dczerinden Nakit Getirisi bulunmaktad\u0131r. Bunlar, geleneksel F\/K oranlar\u0131ndan daha derin i\u00e7g\u00f6r\u00fcler sa\u011flar. Pipeline ge\u00e7i\u015f olas\u0131l\u0131klar\u0131 ve gelir \u00e7e\u015fitlendirme metrikleri, Pfizer gibi ila\u00e7 hisseleri i\u00e7in e\u015fit derecede \u00f6nemlidir."},{"question":"Patent s\u00fcrelerinin dolmas\u0131 Pfizer'in hisse de\u011ferlemesini nas\u0131l etkiler?","answer":"Patent s\u00fcrelerinin dolmas\u0131, analistlerin \"patent u\u00e7urumlar\u0131\" dedi\u011fi durumlar\u0131 yarat\u0131r - amiral gemisi ila\u00e7lardan elde edilen gelirin jenerik rekabetle kar\u015f\u0131la\u015ft\u0131\u011f\u0131 d\u00f6nemler. Regresyon analizimiz, bunun Pfizer hisselerini etkileyen en \u00f6nemli negatif katsay\u0131 (-0.64) oldu\u011funu g\u00f6steriyor. Yat\u0131r\u0131mc\u0131lar, \u00f6n\u00fcm\u00fczdeki 3-5 y\u0131l i\u00e7inde patent s\u00fcresinin dolmas\u0131na kar\u015f\u0131 savunmas\u0131z olan gelir y\u00fczdesini ve risk ayarl\u0131 NPV modelleri kullanarak boru hatt\u0131ndan gelen ikame potansiyelini hesaplamal\u0131d\u0131r."},{"question":"Bireysel yat\u0131r\u0131mc\u0131lar Pfizer hisse senedi i\u00e7in kendi olas\u0131l\u0131k modellerini nas\u0131l olu\u015fturabilirler?","answer":"Pfizer'in gelir b\u00fcy\u00fcmesi, marjlar, Ar-Ge harcamalar\u0131 ve FDA onaylar\u0131 hakk\u0131nda en az 5 y\u0131ll\u0131k \u00fc\u00e7 ayl\u0131k verileri toplayarak ba\u015flay\u0131n. Hisse senedi fiyat hareketleri ile istatistiksel olarak anlaml\u0131 ili\u015fkileri olan fakt\u00f6rleri belirlemek i\u00e7in \u00e7oklu regresyon analizi kullan\u0131n (0.05'in alt\u0131ndaki p-de\u011ferlerine bak\u0131n). Bu fakt\u00f6rler aras\u0131ndaki korelasyon katsay\u0131lar\u0131n\u0131 hesaplay\u0131n ve regresyon katsay\u0131lar\u0131na dayal\u0131 a\u011f\u0131rl\u0131kl\u0131 bir puanlama modeli olu\u015fturun. Pocket Option, bu analitik s\u00fcreci basitle\u015ftirmeye yard\u0131mc\u0131 olabilecek ara\u00e7lar sa\u011flar."},{"question":"Pfizer'in a\u015f\u0131 i\u015f kolu, gelecekteki hisse de\u011fer art\u0131\u015f\u0131 potansiyelinde ne rol oynar?","answer":"A\u015f\u0131lar, Pfizer'\u0131n gelirine yakla\u015f\u0131k %21,7 katk\u0131da bulunmakta ve %7,3 Bile\u015fik Y\u0131ll\u0131k B\u00fcy\u00fcme Oran\u0131 (CAGR) g\u00f6stermektedir. Bu segmentin genel hisse performans\u0131 ile 0,67 korelasyon katsay\u0131s\u0131 vard\u0131r ve bu da onu orta derecede etkili k\u0131lmaktad\u0131r. Segmentin nispeten uzun patent korumas\u0131 (a\u011f\u0131rl\u0131kl\u0131 ortalama 6,8 y\u0131l) gelir istikrar\u0131 sa\u011flamaktad\u0131r. Ancak, onkoloji (%12,4) ve nadir hastal\u0131k (%15,8) segmentlerindeki daha y\u00fcksek b\u00fcy\u00fcme oranlar\u0131, mevcut gelir katk\u0131lar\u0131 daha k\u00fc\u00e7\u00fck olmas\u0131na ra\u011fmen daha b\u00fcy\u00fck hisse de\u011fer art\u0131\u015f\u0131 potansiyeli sa\u011flayabilir."},{"question":"Kurumsal yat\u0131r\u0131mc\u0131lar, Pfizer'i de\u011ferlendirirken d\u00fczenleyici ve politika risklerini nas\u0131l \u00f6l\u00e7er?","answer":"Sofistike yat\u0131r\u0131mc\u0131lar, farkl\u0131 d\u00fczenleyici sonu\u00e7lar i\u00e7in olas\u0131l\u0131k a\u011f\u0131rl\u0131klar\u0131yla senaryo tabanl\u0131 modeller olu\u015fturur. Fiyat Kontrollerinden Kaynaklanan Risk Alt\u0131ndaki Gelir, Co\u011frafi Gelir \u00c7e\u015fitlendirme Endeksi ve Politika Duyarl\u0131l\u0131k Katsay\u0131lar\u0131 (\u00f6nemli politika duyurular\u0131na hisse senedi fiyatlar\u0131n\u0131n tarihsel tepkilerini \u00f6l\u00e7en) gibi metrikler kullanarak politika risk maruziyetini nicelendirirler. Monte Carlo sim\u00fclasyonlar\u0131, bu de\u011fi\u015fkenleri uygun olas\u0131l\u0131k da\u011f\u0131l\u0131mlar\u0131yla birle\u015ftirerek farkl\u0131 d\u00fczenleyici senaryolar alt\u0131nda sonu\u00e7 aral\u0131klar\u0131n\u0131 modellemek i\u00e7in kullan\u0131l\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Pfizer hisse senedinin y\u00fckselip y\u00fckselmeyece\u011fini analiz ederken izlenmesi gereken en \u00f6nemli finansal metrikler nelerdir?","answer":"Kritik metrikler aras\u0131nda Serbest Nakit Ak\u0131\u015f\u0131 Getirisi, Ar-Ge Verimlilik Oran\u0131 (Ar-Ge harcamas\u0131 ba\u015f\u0131na \u00fcretilen geliri \u00f6l\u00e7en), Patent D\u00fczeltilmi\u015f F\/K oran\u0131, FAV\u00d6K\/\u015eirket De\u011feri ve Yat\u0131r\u0131lan Sermaye \u00dczerinden Nakit Getirisi bulunmaktad\u0131r. Bunlar, geleneksel F\/K oranlar\u0131ndan daha derin i\u00e7g\u00f6r\u00fcler sa\u011flar. Pipeline ge\u00e7i\u015f olas\u0131l\u0131klar\u0131 ve gelir \u00e7e\u015fitlendirme metrikleri, Pfizer gibi ila\u00e7 hisseleri i\u00e7in e\u015fit derecede \u00f6nemlidir."},{"question":"Patent s\u00fcrelerinin dolmas\u0131 Pfizer'in hisse de\u011ferlemesini nas\u0131l etkiler?","answer":"Patent s\u00fcrelerinin dolmas\u0131, analistlerin \"patent u\u00e7urumlar\u0131\" dedi\u011fi durumlar\u0131 yarat\u0131r - amiral gemisi ila\u00e7lardan elde edilen gelirin jenerik rekabetle kar\u015f\u0131la\u015ft\u0131\u011f\u0131 d\u00f6nemler. Regresyon analizimiz, bunun Pfizer hisselerini etkileyen en \u00f6nemli negatif katsay\u0131 (-0.64) oldu\u011funu g\u00f6steriyor. Yat\u0131r\u0131mc\u0131lar, \u00f6n\u00fcm\u00fczdeki 3-5 y\u0131l i\u00e7inde patent s\u00fcresinin dolmas\u0131na kar\u015f\u0131 savunmas\u0131z olan gelir y\u00fczdesini ve risk ayarl\u0131 NPV modelleri kullanarak boru hatt\u0131ndan gelen ikame potansiyelini hesaplamal\u0131d\u0131r."},{"question":"Bireysel yat\u0131r\u0131mc\u0131lar Pfizer hisse senedi i\u00e7in kendi olas\u0131l\u0131k modellerini nas\u0131l olu\u015fturabilirler?","answer":"Pfizer'in gelir b\u00fcy\u00fcmesi, marjlar, Ar-Ge harcamalar\u0131 ve FDA onaylar\u0131 hakk\u0131nda en az 5 y\u0131ll\u0131k \u00fc\u00e7 ayl\u0131k verileri toplayarak ba\u015flay\u0131n. Hisse senedi fiyat hareketleri ile istatistiksel olarak anlaml\u0131 ili\u015fkileri olan fakt\u00f6rleri belirlemek i\u00e7in \u00e7oklu regresyon analizi kullan\u0131n (0.05'in alt\u0131ndaki p-de\u011ferlerine bak\u0131n). Bu fakt\u00f6rler aras\u0131ndaki korelasyon katsay\u0131lar\u0131n\u0131 hesaplay\u0131n ve regresyon katsay\u0131lar\u0131na dayal\u0131 a\u011f\u0131rl\u0131kl\u0131 bir puanlama modeli olu\u015fturun. Pocket Option, bu analitik s\u00fcreci basitle\u015ftirmeye yard\u0131mc\u0131 olabilecek ara\u00e7lar sa\u011flar."},{"question":"Pfizer'in a\u015f\u0131 i\u015f kolu, gelecekteki hisse de\u011fer art\u0131\u015f\u0131 potansiyelinde ne rol oynar?","answer":"A\u015f\u0131lar, Pfizer'\u0131n gelirine yakla\u015f\u0131k %21,7 katk\u0131da bulunmakta ve %7,3 Bile\u015fik Y\u0131ll\u0131k B\u00fcy\u00fcme Oran\u0131 (CAGR) g\u00f6stermektedir. Bu segmentin genel hisse performans\u0131 ile 0,67 korelasyon katsay\u0131s\u0131 vard\u0131r ve bu da onu orta derecede etkili k\u0131lmaktad\u0131r. Segmentin nispeten uzun patent korumas\u0131 (a\u011f\u0131rl\u0131kl\u0131 ortalama 6,8 y\u0131l) gelir istikrar\u0131 sa\u011flamaktad\u0131r. Ancak, onkoloji (%12,4) ve nadir hastal\u0131k (%15,8) segmentlerindeki daha y\u00fcksek b\u00fcy\u00fcme oranlar\u0131, mevcut gelir katk\u0131lar\u0131 daha k\u00fc\u00e7\u00fck olmas\u0131na ra\u011fmen daha b\u00fcy\u00fck hisse de\u011fer art\u0131\u015f\u0131 potansiyeli sa\u011flayabilir."},{"question":"Kurumsal yat\u0131r\u0131mc\u0131lar, Pfizer'i de\u011ferlendirirken d\u00fczenleyici ve politika risklerini nas\u0131l \u00f6l\u00e7er?","answer":"Sofistike yat\u0131r\u0131mc\u0131lar, farkl\u0131 d\u00fczenleyici sonu\u00e7lar i\u00e7in olas\u0131l\u0131k a\u011f\u0131rl\u0131klar\u0131yla senaryo tabanl\u0131 modeller olu\u015fturur. Fiyat Kontrollerinden Kaynaklanan Risk Alt\u0131ndaki Gelir, Co\u011frafi Gelir \u00c7e\u015fitlendirme Endeksi ve Politika Duyarl\u0131l\u0131k Katsay\u0131lar\u0131 (\u00f6nemli politika duyurular\u0131na hisse senedi fiyatlar\u0131n\u0131n tarihsel tepkilerini \u00f6l\u00e7en) gibi metrikler kullanarak politika risk maruziyetini nicelendirirler. Monte Carlo sim\u00fclasyonlar\u0131, bu de\u011fi\u015fkenleri uygun olas\u0131l\u0131k da\u011f\u0131l\u0131mlar\u0131yla birle\u015ftirerek farkl\u0131 d\u00fczenleyici senaryolar alt\u0131nda sonu\u00e7 aral\u0131klar\u0131n\u0131 modellemek i\u00e7in kullan\u0131l\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-01T06:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler\",\"datePublished\":\"2025-08-01T06:05:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\"},\"wordCount\":12,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\",\"keywords\":[\"investment\",\"stock\",\"strategy\"],\"articleSection\":[\"Trading\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\",\"name\":\"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\",\"datePublished\":\"2025-08-01T06:05:00+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","og_locale":"tr_TR","og_type":"article","og_title":"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler","og_url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-01T06:05:00+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler","datePublished":"2025-08-01T06:05:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/"},"wordCount":12,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","keywords":["investment","stock","strategy"],"articleSection":["Trading"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","name":"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","datePublished":"2025-08-01T06:05:00+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Pfizer Hissesi Y\u00fckselecek mi: Bilimsel Analiz ve Tahmin Edici \u00d6l\u00e7\u00fctler"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":327928,"slug":"will-pfizer-stock-go-up","post_title":"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc & Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n","href":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/"},"pt_AA":{"locale":"pt_AA","id":327923,"slug":"will-pfizer-stock-go-up","post_title":"O estoque da Pfizer vai subir: An\u00e1lise cient\u00edfica e m\u00e9tricas preditivas","href":"https:\/\/pocketoption.com\/blog\/pt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/327926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=327926"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/327926\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/251337"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=327926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=327926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=327926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}